Table 3.
Risk of prostate cancer recurrence/progression by SLCO2B1 and SLCO1B3 SNP genotypes in a population-based prostate cancer cohort*
| SNP | Genotype | Recurrence/Progression | HR (95% CI) ^ | ||
|---|---|---|---|---|---|
| No (n = 326) |
Yes (n = 143) |
||||
| SLCO2B1 | rs12422149 | GG | 254 (69.2) | 113 (30.8) | 1.00 (referent) |
| GA + AA | 47 (66.2) | 24 (33.8) | 1.09 (0.68 – 1.75) | ||
| SLCO2B1 | rs949069 | GG | 216 (69.5) | 95 (30.6) | 1.00 (referent) |
| GA + AA | 87 (66.4) | 44 (33.6) | 1.19 (0.82 – 1.73) | ||
| SLCO2B1 | rs2712819 | AA | 194 (70.6) | 81 (29.5) | 1.00 (referent) |
| AG + GG | 109 (65.7) | 57 (34.3) | 1.35 (0.95 – 1.91) | ||
| SLCO2B1 | rs2851069 | CC | 116 (70.3) | 49 (29.7) | 1.00 (referent) |
| CT + TT | 184 (66.9) | 91 (33.1) | 1.31 (0.92 – 1.89) | ||
| SLCO2B1 | rs7947726 | GG | 259 (69.1) | 116 (30.9) | 1.00 (referent) |
| AG + AA | 44 (67.7) | 21 (32.3) | 1.21 (0.75 – 1.95) | ||
| SLCO1B3 | rs4149117 | GG | 221 (68.0) | 104 (32.0) | 1.00 (referent) |
| GT + TT | 84 (70.0) | 36 (30.0) | 0.85 (0.57 – 1.26) | ||
| SLCO1B3 | rs3829311 | GG | 206 (68.0) | 97 (32.0) | 1.00 (referent) |
| GA + AA | 98 (69.5) | 43 (30.5) | 0.83 (0.57 – 1.21) | ||
| SLCO1B3 | rs4762803 | CC | 239 (68.3) | 111 (31.7) | 1.00 (referent) |
| CG + GG | 66 (70.2) | 28 (29.8) | 0.86 (0.56 – 1.32) | ||
*
Recurrence/progression data available for 469 cases, Variable number of cases due to failed genotyping
^
Adjusted for age, PSA at diagnosis, Gleason score, tumor stage, primary treatment, BMI and smoking status